Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
about
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveAntibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantationCombination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of ageKinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioningLack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHDThymic T-cell development in allogeneic stem cell transplantationTotal lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisAssociation of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipientsMesenchymal stromal cells: a new tool against graft-versus-host disease?Kinetics of Langerhans cell chimerism in the skin of dogs following 2 Gy TBI allogeneic hematopoietic stem cell transplantation.Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.ABO chimerism determined by real-time polymerase chain reaction analysis after ABO-incompatible haematopoietic stem cell transplantation.Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplantsPharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part IIntracellular disposition of fludarabine triphosphate in human natural killer cells.Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation.Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies.TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.Bone marrow T cells are superior to splenic T cells to induce chimeric conversion after non-myeloablative bone marrow transplantationImportance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation.Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation.Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns.Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of HeterozygosityLineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation.Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?Indiscernible Benefit of Double-Unit Umbilical Cord Blood Transplantation in Children: A Single-Center Experience From Hong Kong.Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning.Trogocytosis in allogeneic transplants: donor cells take on the recipients identity.Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.
P2860
Q28388806-DF5861A0-4923-4FAD-9599-8A7958E4BBACQ30238945-6D0C0DBE-F6AD-49C1-A04F-256429E94E06Q34175259-A5CABD75-055B-4C32-96A0-08C77CEAFC43Q34348102-BE7DC41E-EF41-4696-9318-9F22C382BB91Q34463602-69A3B831-14A9-4AAC-BCBC-D4167F402B0EQ34543056-FF02B799-428E-49FE-8070-9F927C029B6BQ34598248-1C584F28-D220-451D-B6A3-FAC5FB2E7452Q34600830-AE02E0D7-667C-4785-BC6E-117E253E8045Q34707286-B5B43B38-D64D-4EAB-B585-F5EF1F2A0122Q35083246-B552709A-82B1-48FC-9E0A-6DCECA30F2FAQ35317371-6E4B78B2-00EC-460A-A9EB-FCF5A12E1FFCQ35735663-6D7FBE6B-6DA4-4308-8AE5-A2EE34B17276Q35811940-05C424A3-8771-47C0-9792-FA9757ABF63DQ35848391-29D38F4D-0790-4EA1-966D-B666EB4FD0A2Q36002793-667A8734-3CDF-4667-9A04-4F8B030033E4Q36002866-754ACE9D-0FD1-4E0A-B358-3ACE9EC920B5Q36010605-08E41CD0-441C-47C9-A5D1-5B2F7BB35418Q36426327-33DF8B14-8177-4852-BB82-D0308F4CDA4EQ36569021-9C8458E4-C34D-46A2-9B8E-D80F9691D3C9Q36727857-A5FBEB7F-3C26-4D64-AA01-68FB61935DFCQ36777599-CE63D0CC-36C0-49D5-9FF1-DF76EF8620CDQ37111568-D97D726F-E921-4862-AE6B-D9BCF5E96438Q37142672-FAC26979-2B3F-4557-ADD6-9A84812AD14EQ37207777-AF3D8A8B-9A71-4694-871E-0B1B2367F36AQ37291642-9AA95414-7F23-4320-AC79-8016E88E1CC0Q37320975-B9030EB0-64E0-4B54-A54D-A50DC06055ABQ37674071-AEB1BF67-0C54-4388-ADC3-AEF3A6EB6F54Q37894465-5911F78C-AAB0-447F-9E3C-8E49A4661E1BQ38029953-EFB8A225-3291-4F13-98D7-ABC67500DC10Q38105635-5752BA48-A6DC-439F-83EA-62D8E83EC2A5Q38694213-206937B0-A4EE-44C0-86CB-EB876B5FEF27Q38909764-5947002E-9AD0-4FF2-9498-879F653D62C4Q39764454-F6B1B66E-02B8-4EEF-BFF1-9474DE7322ADQ39903954-DBED7F55-FFFE-40FF-8E9B-3EE7299E7C31Q40472138-70DBDF0B-E190-41B6-9044-DB29613FA39BQ41179451-810DF25D-D9AE-4568-B580-5AC7A6A35CA6Q41947441-E7D884F6-9F90-4509-AE14-2A4BFDEA102DQ43263268-FE7D712F-AE9D-447A-A7AC-DEFFE9B9053BQ43794581-4EEE2D74-B2FE-40E1-88AE-E567762FE8CFQ44300919-A54AE5D2-5F25-490F-B347-708D2343AF85
P2860
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chimerism and outcomes after a ...... nonmyeloablative conditioning.
@ast
Chimerism and outcomes after a ...... nonmyeloablative conditioning.
@en
type
label
Chimerism and outcomes after a ...... nonmyeloablative conditioning.
@ast
Chimerism and outcomes after a ...... nonmyeloablative conditioning.
@en
prefLabel
Chimerism and outcomes after a ...... nonmyeloablative conditioning.
@ast
Chimerism and outcomes after a ...... nonmyeloablative conditioning.
@en
P2860
P356
P1433
P1476
Chimerism and outcomes after a ...... nonmyeloablative conditioning.
@en
P2093
B M Sandmaier
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404335
P577
2006-07-27T00:00:00Z